Barclays PLC Buys 141,949 Shares of AdaptHealth Corp. (NASDAQ:AHCO)

Barclays PLC raised its position in AdaptHealth Corp. (NASDAQ:AHCO) by 361.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 181,240 shares of the company’s stock after purchasing an additional 141,949 shares during the period. Barclays PLC owned approximately 0.13% of AdaptHealth worth $2,034,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of AHCO. FMR LLC raised its stake in AdaptHealth by 9.3% during the 3rd quarter. FMR LLC now owns 7,350,549 shares of the company’s stock worth $82,547,000 after buying an additional 624,645 shares during the period. Reinhart Partners LLC. grew its position in shares of AdaptHealth by 45.2% in the 3rd quarter. Reinhart Partners LLC. now owns 6,198,642 shares of the company’s stock valued at $69,611,000 after purchasing an additional 1,929,339 shares during the period. State Street Corp raised its holdings in AdaptHealth by 19.8% during the 3rd quarter. State Street Corp now owns 4,124,284 shares of the company’s stock worth $46,316,000 after buying an additional 681,816 shares during the period. Segall Bryant & Hamill LLC boosted its holdings in shares of AdaptHealth by 15.5% in the third quarter. Segall Bryant & Hamill LLC now owns 3,701,808 shares of the company’s stock valued at $41,571,000 after buying an additional 496,453 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in AdaptHealth by 43.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,327,738 shares of the company’s stock valued at $23,277,000 after acquiring an additional 710,131 shares in the last quarter. 82.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank of Canada reduced their price objective on AdaptHealth from $13.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Robert W. Baird reduced their target price on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group lowered their price target on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Truist Financial reduced their price objective on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, UBS Group lowered their target price on AdaptHealth from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

AdaptHealth Stock Down 2.6 %

Shares of AHCO stock opened at $9.79 on Friday. AdaptHealth Corp. has a 52-week low of $6.46 and a 52-week high of $11.90. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -5.93, a PEG ratio of 1.36 and a beta of 1.10. The firm’s 50-day moving average is $10.07 and its 200-day moving average is $10.43.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). AdaptHealth had a negative net margin of 6.57% and a positive return on equity of 9.62%. The business had revenue of $805.90 million during the quarter, compared to analyst estimates of $809.32 million. During the same period in the previous year, the business earned $0.19 earnings per share. The business’s quarterly revenue was up .2% on a year-over-year basis. Sell-side analysts predict that AdaptHealth Corp. will post 0.88 EPS for the current year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.